HOW PRIORITIZATION OF TREATMENT LINES CAN ENHANCE PATIENT’S QUALITY OF LIFE AND UTILIZATION OF RESOURCES FOR METASTATIC PROSTATE CANCER?

Author(s)

ABSTRACT WITHDRAWN

Background: Prostate cancer is known to be the sixth most common cancer in the world and the third most common cancer among men .Although the success of current treatments for prostate cancer most patients eventually will progress to a phase of the disease that is metastatic and shows resistance to further hormonal manipulation. According to WHO report about prostate cancer disease, showed that patients in resource-limited regions typically present with advanced disease. After developing of new treatments for metastatic castration-resistant. A question was raised how policy of health system can enhance patient’s quality of life and utilization of resources through Prioritization of treatment lines The rationale intended for this study is to determine impact of using abiraterone prior to docetaxel for enhancing patient’s quality of life and utilization of resources for a Limited Resources country like Egypt. Methods A cost-effectiveness analysis from the payer perspective the Ministry of Health and Population was conducted. To maximize health gain for the patients while ensuring the most efficient use of the finite resources available. Markov chain simulation model the model used a hypothetical was applied with three health states. First line metastatic until disease progression the second state was (best supportive care) the third state was death. The structure reflects the natural history of prostate cancer and current treatment. Results After five years, total costs, QALY and ICER are shown in the following table. During the five-year time horizon, total QALY gained for the abiraterone arm was 295 QALY. Total QALY gained for Docetaxel arm was 197 QALY. That yields a difference of QALY was 98. Conclusions: The result of this study suggested that the positive impact of using Abiraterone strategy prior Docetaxel strategy through QALY gained and 1% Increase in the total budget. In case of penetration with 10% of Abiraterone.

Conference/Value in Health Info

2019-05, ISPOR 2019, New Orleans, LA, USA

Value in Health, Volume 22, Issue S1 (2019 May)

Code

PCN44

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×